

2009

Maria Ricci Memorial Lectureship in Medical Oncology



Queen's
UNIVERSITY

Insulin and Breast Cancer – A Potential Therapeutic Target?



Dr. Pamela Goodwin, MD, MSc, FRCP(C)

Dr. Pamela Goodwin has been actively involved in research relating to host factors in breast cancer for the past 20 years. Early in her career, she became intrigued with the possibility that lifestyle, especially obesity, might impact outcomes of women diagnosed with breast cancer. She began a program of research that focused on the role of lifestyle factors, including nutrition, exercise and related factors in the clinical course of breast cancer. She has led a number of studies which investigate the complex interactions between body size, nutrition, exercise and physiologic mediators such as insulin, IGF-I and vitamin D, examining the impact of these factors on survival of women diagnosed with breast cancer. More

recently, Dr. Goodwin has begun investigating the status of long-term breast cancer survivors and the influences of hereditary factors, vitamin D and metformin on breast cancer outcomes.

Dr. Goodwin is a Professor of Medicine at the University of Toronto, with cross appointments in the Department of Health Policy, Management and Evaluation and in the School of Graduate Studies. She is a Scientist in the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, Director of the hospital's Marvelle Koffler Breast Centre and holder of the Marvelle Koffler Chair in Breast Research. She is also Head of the Medical Oncology Breast Group at Princess Margaret Hospital.

Wednesday, 25 November 2009

4:30 pm

Cancer Research Institute, Rm 100

presented by

NCIC Clinical Trials Group

NCIC Groupe des essais cliniques

**This lectureship was established in September 2007 by a donation from
GlaxoSmithKline Inc. in memory of Maria Ricci**